Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F. Pignata S, et al. Among authors: pisano c. J Clin Oncol. 2017 Oct 10;35(29):3347-3353. doi: 10.1200/JCO.2017.73.4293. Epub 2017 Aug 21. J Clin Oncol. 2017. PMID: 28825853 Clinical Trial.
Prognostic value of CD40 in adult soft tissue sarcomas.
Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F, De Rosa V, Mozzillo N, Ravo V, Morrica B, Gallo C, Pisano C, Napolitano M, Ascierto PA, Iaffaioli RV, Apice G. Ottaiano A, et al. Among authors: pisano c. Clin Cancer Res. 2004 Apr 15;10(8):2824-31. doi: 10.1158/1078-0432.ccr-0139-03. Clin Cancer Res. 2004. PMID: 15102691
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F. Pignata S, et al. Among authors: pisano c. BMC Cancer. 2006 Jan 7;6:5. doi: 10.1186/1471-2407-6-5. BMC Cancer. 2006. PMID: 16398939 Free PMC article. Clinical Trial.
Significance of erb-B2 immunoreactivity in cervical cancer.
Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, DiVagno G, Silvestro G, Tambaro R, Formato R, Iaffaioli VR, Di Maio M, Pignata S. Califano D, et al. Among authors: pisano c. Front Biosci. 2006 Sep 1;11:2071-6. doi: 10.2741/1949. Front Biosci. 2006. PMID: 16720293
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Pignata S, et al. Among authors: pisano c. BMC Cancer. 2006 Aug 1;6:202. doi: 10.1186/1471-2407-6-202. BMC Cancer. 2006. PMID: 16882344 Free PMC article. Clinical Trial.
403 results